<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222454</url>
  </required_header>
  <id_info>
    <org_study_id>CL-K1002-P006</org_study_id>
    <nct_id>NCT02222454</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers</brief_title>
  <official_title>A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KLOX Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KLOX Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of these case series is to evaluate the safety and tolerability of the&#xD;
      KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with&#xD;
      stage II or III pressure ulcers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of the KLOX BioPhotonic System in patients with stage II or III pressure ulcers.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Occurrence of adverse events, serious adverse events and incidents; pain assessment with Visual Analog Scale; clinical laboratory parameters; vital signs; physical examination; percentage of patients with clinical infection requiring systemic antimicrobial therapy; concomitant medications and treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal frequency of treatment with KLOX BioPhotonic System on stage II and III pressure ulcers.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Exploration of the optimal frequency of treatment with KLOX BioPhotonic System on stage II and III pressure ulcers, with dosing flexibility according to Investigator's clinical opinion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete wound closure.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete wound closure.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of wound breakdown.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound area reduction over time.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound volume reduction over time.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact of treatment on Health-related quality of life.</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Pressure Ulcers Stage II</condition>
  <condition>Pressure Ulcers Stage III</condition>
  <arm_group>
    <arm_group_label>KLOX BioPhotonic System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for pressure ulcers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KLOX BioPhotonic System</intervention_name>
    <description>KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.</description>
    <arm_group_label>KLOX BioPhotonic System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 years of age and older;&#xD;
&#xD;
          -  The subject or legal guardian must have signed an informed consent form;&#xD;
&#xD;
          -  Female of child bearing potential must have a negative pregnancy test result at&#xD;
             Baseline and both male and female patients must be willing to adhere to a&#xD;
             medically-accepted birth control method during the course of the study;&#xD;
&#xD;
          -  Willingness to return for all study visits;&#xD;
&#xD;
          -  Stage II or III pressure ulcer (as per NPUAP Staging Guidelines), present for more&#xD;
             than 4 weeks (up to Screening visit), located in the ischial, trochanteric, coccygeal,&#xD;
             thoracic or abdominal regions. Lower extremity pressure ulcers, such as heel ulcers,&#xD;
             are acceptable provided that diabetic foot ulcers are ruled out if the patient has&#xD;
             diabetes. Surface dimensions of ulcer must be between 2 to 64 cm2 inclusive but&#xD;
             longest diameter must not exceed 10 cm. Depth must not exceed 5 cm;&#xD;
&#xD;
          -  Wound area has not changed by more than +/- 30% between Screening visit and Week&#xD;
             1/Visit 1 (before treatment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pressure ulcer present for more than 18 months;&#xD;
&#xD;
          -  The ulcer to be treated is planned for operative debridement;&#xD;
&#xD;
          -  The ulcer has significant necrotic tissue (e.g., more than 20% of the ulcer area);&#xD;
&#xD;
          -  Major uncontrolled medical disorder(s) such as serious cardiovascular, renal, liver or&#xD;
             pulmonary disease, lupus, palliative care or sickle cell anemia;&#xD;
&#xD;
          -  Severe or significant hypoalbuminemia (albuminemia &lt; 30 g/L, and/or pre-albumin &lt; 5&#xD;
             mg/dL), or hypoproteinemia (proteinemia &lt; 55g/L);&#xD;
&#xD;
          -  Patient with moderate to severe anemia (Hb &lt; 90g/L);&#xD;
&#xD;
          -  Patient currently treated for an active malignant disease;&#xD;
&#xD;
          -  Patient with history of malignancy within the wound;&#xD;
&#xD;
          -  Patient with history of radiation therapy to the wound region;&#xD;
&#xD;
          -  Patient with prior diagnosis of active malignant disease who is less than 1 year&#xD;
             disease-free;&#xD;
&#xD;
          -  Patient with a known osteomyelitis or active cellulitis;&#xD;
&#xD;
          -  Patients that are immunosuppressed or on high dose chronic steroid use;&#xD;
&#xD;
          -  Patients on systemic corticosteroids (a completion of corticosteroid course at least&#xD;
             30 days prior to study enrolment is required);&#xD;
&#xD;
          -  Patient with active or systemic infection (note that the patient is however eligible&#xD;
             for re-screening after the systemic infection has subsided);&#xD;
&#xD;
          -  Patients with severely uncontrolled diabetes mellitus (defined as A1C &gt; 12%);&#xD;
&#xD;
          -  Dermatologic comorbid disease (e.g., cutis laxa or collagen vascular disease);&#xD;
&#xD;
          -  Active bleeding;&#xD;
&#xD;
          -  Pregnancy, or breast feeding;&#xD;
&#xD;
          -  Patients with bleeding diathesis;&#xD;
&#xD;
          -  Patients on Warfarin or IV Heparin;&#xD;
&#xD;
          -  The subject has any physical or psychiatric condition that in the Investigator's&#xD;
             opinion would warrant exclusion from the study or prevent the subject from completing&#xD;
             the study (e.g., severe morbid obesity, recent hip fracture, suspected non-compliance,&#xD;
             etc.);&#xD;
&#xD;
          -  Patients with ulcers from burns (from exposure to high heat), venous ulcers or&#xD;
             diabetic foot ulcers;&#xD;
&#xD;
          -  Concurrent disease or drugs known to induce severe photosensitivity of the skin, such&#xD;
             as porphyria;&#xD;
&#xD;
          -  Patient has received biological-based therapy in any wound within 3 months of&#xD;
             Screening;&#xD;
&#xD;
          -  Concurrent participation in another clinical trial that involves an investigational&#xD;
             drug or device that wound interfere with this study;&#xD;
&#xD;
          -  Previous participation in other interventional wound healing clinical investigation&#xD;
             within the 60 days prior to Screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Keast, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawton Research Institute, London, Ontario, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Calgary Center for Clinical Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawton Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 2R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Jerome Medical Research Inc.</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pressure Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

